Bristol-Myers Squibb Company (BMY)

55.96
NYSE : Health Care
Prev Close 55.80
Day Low/High 55.30 / 56.11
52 Wk Low/High 49.03 / 77.12
Avg Volume 12.74M
Exchange NYSE
Shares Outstanding 1.67B
Market Cap 93.25B
EPS 0.90
P/E Ratio 18.12
Div & Yield 1.52 (2.70%)

Latest News

Healthcare Bill Up for House Vote Wed. Hailed as Game-Changer, Blasted as Pharma Handout

Healthcare Bill Up for House Vote Wed. Hailed as Game-Changer, Blasted as Pharma Handout

There is no shortage of opinions and politics as the House prepares for a vote Nov. 30 on 21st Century Cures Act.

Is Bristol-Myers Feeling Better? Not Really

Is Bristol-Myers Feeling Better? Not Really

The stock will eventually rebase, but we don't know where or when.

Home Depot, Lowe's, Best Buy: Doug Kass' Views

Home Depot, Lowe's, Best Buy: Doug Kass' Views

Doug Kass shares his thoughts on the Trump world and how large-cap biotechs are doing.

C, AAPL, FB: Jim Cramer's Views

C, AAPL, FB: Jim Cramer's Views

Cramer shares his views on how much further Citigroup and Goldman Sachs have to run and cautions that you can't wait for everyone to love a stock.

Biotech School: How to Use Kaplan-Meier Survival Curves to Become a Smarter Investor

Biotech School: How to Use Kaplan-Meier Survival Curves to Become a Smarter Investor

Interpreting 'K-M curves' correctly is an important tool for biotech investors.

European Commission Approves Bristol-Myers Squibb's Opdivo (nivolumab) For The Treatment Of Adult Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant And Treatment With Brentuximab Vedotin

European Commission Approves Bristol-Myers Squibb's Opdivo (nivolumab) For The Treatment Of Adult Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant And Treatment With Brentuximab Vedotin

Bristol-Myers Squibb Company (NYSE: BMY) today announced the European Commission approved Opdivo (nivolumab) for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) after...

How to Be a Smarter Biotech Investor

How to Be a Smarter Biotech Investor

Interpreting "K-M curves" correctly is an important tool for biotech investors.

Cramer: Trump Rally is a FANG + FANG Affair

Cramer: Trump Rally is a FANG + FANG Affair

Today high-growth tech and natural resources stocks are both going higher without sending much lower at all.

Watch the Yield on the Five-Year Note

The 1.80% area has been a serious lid on yields.

Bristol-Myers Squibb Presents New Data At IASLC 17th World Conference On Lung Cancer Underscoring Progress And Leadership In Broad Lung Development Program

Bristol-Myers Squibb Presents New Data At IASLC 17th World Conference On Lung Cancer Underscoring Progress And Leadership In Broad Lung Development Program

Bristol-Myers Squibb Company (NYSE:BMY) today announced new data to be presented at the International Association for the Study of Lung Cancer (IASLC) 17 th World Conference on Lung Cancer (WCLC) in Vienna, Austria from...

Bristol-Myers Squibb And Enterome Announce Immuno-Oncology Collaboration Focused On Microbiome-Derived Biomarkers, Drug Targets And Bioactive Molecules

Bristol-Myers Squibb And Enterome Announce Immuno-Oncology Collaboration Focused On Microbiome-Derived Biomarkers, Drug Targets And Bioactive Molecules

Bristol-Myers Squibb Company (NYSE:BMY) and Enterome, a pioneer in the development of pharmaceuticals and diagnostics based on the gut microbiome, announced that they have entered into an Immuno-Oncology focused...

Bullish and Bearish Chart Reversals

What stocks have changed direction in the past week.

Bristol-Myers Squibb Showcases Rheumatoid Arthritis And Immunoscience Commitment With Depth Of Research At 2016 American College Of Rheumatology And Association Of Rheumatology Health Professionals Annual Meeting

Bristol-Myers Squibb Showcases Rheumatoid Arthritis And Immunoscience Commitment With Depth Of Research At 2016 American College Of Rheumatology And Association Of Rheumatology Health Professionals Annual Meeting

Bristol-Myers Squibb Company (NYSE:BMY) today unveiled rheumatoid arthritis (RA) and autoimmune disease data being presented at the 2016 Annual Meeting of the American College of Rheumatology (ACR) and the Association of...

Opdivo (nivolumab) And Yervoy (ipilimumab) Regimen Shows Promising Efficacy And Safety In Previously Treated Patients With Advanced Form Of Bladder Cancer

Opdivo (nivolumab) And Yervoy (ipilimumab) Regimen Shows Promising Efficacy And Safety In Previously Treated Patients With Advanced Form Of Bladder Cancer

Bristol-Myers Squibb Company (NYSE:BMY) announced today additional results from the Phase 1/2 open-label CheckMate-032 trial investigating two combination schedules of  Opdivo (nivolumab) plus Yervoy...

Interim Phase 1/2 Data Show Encouraging Clinical Benefit For Lirilumab In Combination With Opdivo (nivolumab) In Patients With Advanced Platinum Refractory Squamous Cell Carcinoma Of The Head And Neck

Interim Phase 1/2 Data Show Encouraging Clinical Benefit For Lirilumab In Combination With Opdivo (nivolumab) In Patients With Advanced Platinum Refractory Squamous Cell Carcinoma Of The Head And Neck

Bristol-Myers Squibb Company (NYSE:BMY) and Innate Pharma SA (Euronext Paris: FR0010331421 - IPH) today announced an interim efficacy analysis from a Phase 1/2 study of the combination of lirilumab and Opdivo...

Phase 1/2 Data Combining Urelumab With Opdivo (nivolumab) In Hematologic And Solid Tumors Suggest Increased Antitumor Effect In Patients With Melanoma

Phase 1/2 Data Combining Urelumab With Opdivo (nivolumab) In Hematologic And Solid Tumors Suggest Increased Antitumor Effect In Patients With Melanoma

Bristol-Myers Squibb Company (NYSE:BMY) today announced safety and efficacy data from a Phase 1/2 study of urelumab in combination with Opdivo (nivolumab) in patients with hematologic and solid tumors, including...

Bristol-Myers Squibb To Showcase New Data Spanning Rheumatoid Arthritis And Other Autoimmune Diseases At 2016 American College Of Rheumatology And Association Of Rheumatology Health Professionals Annual Meeting

Bristol-Myers Squibb To Showcase New Data Spanning Rheumatoid Arthritis And Other Autoimmune Diseases At 2016 American College Of Rheumatology And Association Of Rheumatology Health Professionals Annual Meeting

Bristol-Myers Squibb Company (NYSE:BMY) today announced that 23 abstracts related to ORENCIA ® (abatacept) and the company's immunoscience pipeline will be presented at the 2016 annual meeting of the American...

Bristol-Myers Squibb Enters Into New Collaboration With Johns Hopkins Focused On Immuno-Oncology Research

Bristol-Myers Squibb Enters Into New Collaboration With Johns Hopkins Focused On Immuno-Oncology Research

Bristol-Myers Squibb Company (NYSE:BMY) announced today that the company has entered into a five-year research collaboration with the Johns Hopkins University.

(Graphic: Business Wire)

(Graphic: Business Wire)

Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc.

Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement With Nitto Denko For Targeted SiRNA Therapy In Advanced Non-alcoholic Steatohepatitis (NASH) And Cirrhosis Due To NASH

Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement With Nitto Denko For Targeted SiRNA Therapy In Advanced Non-alcoholic Steatohepatitis (NASH) And Cirrhosis Due To NASH

Bristol-Myers Squibb Company (NYSE:BMY) and Nitto Denko Corporation (Nitto) (6988:Tokyo) today announced the companies have entered into an agreement granting Bristol-Myers Squibb exclusive worldwide rights for the...

Opdivo (nivolumab) Demonstrates Overall Survival Benefit In Patients With Unresectable Advanced Or Recurrent Gastric Cancer In Phase 3 Study

Opdivo (nivolumab) Demonstrates Overall Survival Benefit In Patients With Unresectable Advanced Or Recurrent Gastric Cancer In Phase 3 Study

Bristol-Myers Squibb Company (NYSE:BMY) announced today that ONO-4538-12, a Phase 3, randomized, double-blind clinical trial evaluating the efficacy and safety of Opdivo (nivolumab) in patients with unresectable...

Drug and Biotech Stocks Rise as Price Clampdown Fears Ease Under Trump Presidency (Updated)

Drug and Biotech Stocks Rise as Price Clampdown Fears Ease Under Trump Presidency (Updated)

How health care investors deal with Donald Trump as the next U.S. president and Republicans maintaining control of Congress is hard to forecast because few envisioned this scenario playing out.

Bristol-Myers Squibb To Take Part In Stifel 2016 Health Care Conference

Bristol-Myers Squibb To Take Part In Stifel 2016 Health Care Conference

Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Stifel 2016 Health Care Conference on Wednesday, November 16, 2016, in New York.

Bristol-Myers Squibb And Infinity Pharmaceuticals Announce Clinical Collaboration To Evaluate Opdivo (Nivolumab) In Combination With IPI-549 In Advanced Solid Tumors

Bristol-Myers Squibb And Infinity Pharmaceuticals Announce Clinical Collaboration To Evaluate Opdivo (Nivolumab) In Combination With IPI-549 In Advanced Solid Tumors

-- Evaluation of IPI-549 as a Monotherapy Continuing, with Combination Portion of Phase 1 Study Expected to Begin This Fall --

5 Things You Must Know Before the Market Opens Wednesday

5 Things You Must Know Before the Market Opens Wednesday

Stock futures are tumbling Wednesday but are well off their lows as Republican Donald Trump is elected the next president of the United States in a surprising victory.